On June 11, DualityBio-B fell 5.61% in regular trading, trading at 165.6 HKD/share, with trading volume of approximately 42.53 million HKD.

On the news front, despite the company announcing on June 10 that its STAR Market IPO coaching had passed Shanghai CSRC verification and continuing share buybacks, selling pressure persisted. The company repurchased 10,000 shares on June 10 at a cost of approximately 1.674 million HKD. A prior rebound of over 6% on June 5 — driven by ASCO clinical data and intensive buyback activity — proved short-lived, with the stock retreating steadily from its recent high.

The broader biotechnology sector experienced systematic selling pressure, with BeiGene down 5.71%, Akeso down 4.38%, SKB Bio down 4.53%, 3SBio down 3.76%, and Innovent Bio down 3.30%, amplifying individual stock weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)